{"id":43423,"date":"2025-09-11T12:04:48","date_gmt":"2025-09-11T06:34:48","guid":{"rendered":"https:\/\/newstrackbhopal.com\/index.php\/2025\/09\/11\/raainbow-phase-2-3-paediatric-alopecia-areata-trial-featuring-cliniexperts-research-services-published-in-british-journal-of-dermatology\/"},"modified":"2025-09-11T12:04:48","modified_gmt":"2025-09-11T06:34:48","slug":"raainbow-phase-2-3-paediatric-alopecia-areata-trial-featuring-cliniexperts-research-services-published-in-british-journal-of-dermatology","status":"publish","type":"post","link":"https:\/\/newstrackbhopal.com\/index.php\/2025\/09\/11\/raainbow-phase-2-3-paediatric-alopecia-areata-trial-featuring-cliniexperts-research-services-published-in-british-journal-of-dermatology\/","title":{"rendered":"RAAINBOW Phase 2\/3 Paediatric Alopecia Areata Trial Featuring CliniExperts Research Services Published in British Journal of Dermatology"},"content":{"rendered":"
\n

New Delhi [India], September 11:\u00a0<\/span><\/strong> CliniExperts Research Services is proud to announce its contribution to the <\/span>RAAINBOW Phase 2\/3 global clinical trial<\/span><\/strong>, evaluating Cinainu, the world\u2019s first botanical topical drug candidate for the treatment of <\/span>moderate to severe paediatric Alopecia Areata (AA)<\/span><\/strong>. The groundbreaking results have been published in the British Journal of Dermatology on 16th of July, 2025.\u00a0<\/span><\/p>\n

CliniExperts Research Services played a key role in conducting the India arm of the trial, managing\u00a0<\/span>clinical operations across multiple sites, data analysis, and reporting<\/span><\/strong>, in collaboration with\u00a0<\/span>Legacy Healthcare<\/span><\/strong>, the Switzerland-based biopharmaceutical company leading the trial.<\/span><\/p>\n

About Paediatric Alopecia Areata & Cinainu<\/span><\/strong><\/h2>\n

Alopecia Areata (AA) is an autoimmune disorder causing patchy hair loss, with limited safe treatment options for children. Cinainu is a patented\u00a0<\/span>botanical topical solution<\/span><\/strong>\u00a0targeting inflammation, apoptosis, and oxidative stress in AA physiology.<\/span><\/p>\n

About the RAAINBOW Trial<\/span><\/strong><\/h2>\n

\u25cfmultinational, randomized, double-blind, placebo-controlled, multicentric Phase 2\/3 trial<\/span><\/strong>\u00a0in paediatric AA.<\/span>
\n<\/span><\/p>\n

\u25cfConducted across\u00a0<\/span>12 sites in 4 countries<\/span><\/strong>\u00a0with\u00a0<\/span>107 patients aged 2\u201318 years<\/span><\/strong>
\n<\/span><\/p>\n

\u25cfIndia\u2019s contribution:<\/span><\/strong> Led by CliniExperts Research Services, which ensured compliance with safety, regulatory, and quality standards while delivering comprehensive data analysis.<\/span><\/p>\n

\u25cfResults of the trial are available on the\u00a0<\/span><\/strong>BJD website\u00a0<\/span><\/u><\/strong><\/a><\/p>\n

Leadership Voices<\/span><\/strong><\/h2>\n

Saad Harti, Founder & CEO, Legacy Healthcare,<\/strong> said, \u201cBeyond its efficacy in regrowing patients\u2019 scalp hair, Cinainu has been shown to treat this autoimmune disease without immunosuppression-related adverse events, and with persistent efficacy, which, to our knowledge, is a first.\u00a0Publication in the British Journal of Dermatology marks a key milestone supporting Cinainu\u2019s efficacy and safety.\u201d<\/span><\/p>\n

CliniExperts Research Services<\/span><\/strong> stated, \u201cWe are honoured to have contributed to the successful execution of the Indian arm of this global trial. Our role in ensuring quality conduct and delivering country-specific trial design demonstrates CliniExperts\u2019 growing leadership in global dermatology research.\u201d<\/span><\/p>\n

About Legacy Healthcare<\/span><\/strong><\/h2>\n

Legacy Healthcare is a Switzerland-based biopharmaceutical company pioneering safe, plant-based therapeutics for chronic diseases.<\/span><\/p>\n

About CliniExperts Research Services<\/span><\/strong><\/h2>\n

CliniExperts Research Services is a leading clinical research organization based in India, specializing in high-quality clinical operations, regulatory expertise, and data analysis across multiple therapeutic areas. Its strong commitment to innovation and compliance enables global biopharmaceutical partners to achieve breakthrough outcomes.<\/span><\/p>\n

To know more details, please visit: <\/span>CliniExperts Research \u00a0Services\u00a0<\/span><\/u><\/a><\/p>\n

If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

New Delhi [India], September 11:\u00a0 CliniExperts Research Services is proud to announce its contribution to the RAAINBOW Phase 2\/3 global clinical trial, evaluating Cinainu, the world\u2019s first botanical topical drug candidate for the treatment of moderate to severe paediatric Alopecia Areata (AA). The groundbreaking results have been published in the British Journal of Dermatology on […]<\/p>\n","protected":false},"author":1,"featured_media":43424,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[56],"tags":[631],"class_list":["post-43423","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-health"],"wpmagazine_modules_lite_featured_media_urls":{"thumbnail":["https:\/\/newstrackbhopal.com\/wp-content\/uploads\/2025\/09\/RAAINBOW-150x150.jpg",150,150,true],"cvmm-medium":["https:\/\/newstrackbhopal.com\/wp-content\/uploads\/2025\/09\/RAAINBOW-300x300.jpg",300,300,true],"cvmm-medium-plus":["https:\/\/newstrackbhopal.com\/wp-content\/uploads\/2025\/09\/RAAINBOW-305x207.jpg",305,207,true],"cvmm-portrait":["https:\/\/newstrackbhopal.com\/wp-content\/uploads\/2025\/09\/RAAINBOW-400x600.jpg",400,600,true],"cvmm-medium-square":["https:\/\/newstrackbhopal.com\/wp-content\/uploads\/2025\/09\/RAAINBOW-600x600.jpg",600,600,true],"cvmm-large":["https:\/\/newstrackbhopal.com\/wp-content\/uploads\/2025\/09\/RAAINBOW-1024x675.jpg",1024,675,true],"cvmm-small":["https:\/\/newstrackbhopal.com\/wp-content\/uploads\/2025\/09\/RAAINBOW-130x95.jpg",130,95,true],"full":["https:\/\/newstrackbhopal.com\/wp-content\/uploads\/2025\/09\/RAAINBOW.jpg",1200,675,false]},"categories_names":{"56":{"name":"Health","link":"https:\/\/newstrackbhopal.com\/index.php\/category\/health\/"}},"tags_names":{"631":{"name":"health","link":"https:\/\/newstrackbhopal.com\/index.php\/tag\/health\/"}},"comments_number":"0","_links":{"self":[{"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/posts\/43423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/comments?post=43423"}],"version-history":[{"count":0,"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/posts\/43423\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/media\/43424"}],"wp:attachment":[{"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/media?parent=43423"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/categories?post=43423"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/tags?post=43423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}